. 2021 May 21;13(1):e12177. doi: 10.1002/dad2.12177

TABLE 1.

Demographics, CSF biomarkers, and clinical characteristics of study participants

	NC	MCI	Dementia	P
Number	55	87	45
Age, year	75.8 (4.9)	73.8 (7.4)	74.6 (8.8)	.302
Sex, female	25 (45.5)	27 (31.0)	20 (44.4)	.146
Education, year	16.2 (2.3)	15.8 (3.1)	15.0 (3.2)	.159
CSF biomarkers
Aβ_1‐42, pg/mL	213.0 (50.9) ^a,b	159.8 (51.2) ^a	152.2 (42.4) ^b	< .001
tau, pg/mL	71.8 (29.4) ^a,b	96.8 (46.9) ^a,c	122.0 (66.4) ^b,c	< .001
P‐tau181p, pg/mL	22.8 (10.4) ^a,b	33.4 (15.7) ^a	37.6 (18.8) ^b	< .001
α‐syn, ng/mL	0.52 (0.14)	0.54 (0.14)	0.56 (0.15)	.288
Aβ‐positivity	18 (32.7) ^a,b	66 (75.9) ^a,c	39 (86.7) ^b,c	< .001
Baseline cognitive scores
Attention	–0.18 (0.88) ^b	–0.40 (0.87) ^c	‐0.83 (0.61) ^b,c	< .001
Executive function	0.05 (0.63) ^a,b	–0.69 (1.00) ^a,c	‐2.16 (1.51) ^b,c	< .001
Language	–0.15 (0.69) ^a,b	–0.78 (1.00) ^a,c	‐1.42 (1.07) ^b,c	< .001
Memory	–0.08 (0.59) ^a,b	–1.28 (0.83) ^a,c	‐1.84 (0.57) ^b,c	< .001
Visuospatial function	–0.03 (0.66) ^a,b	–0.63 (1.05) ^a,c	‐1.34 (1.07) ^b,c	< .001
MMSE score	29.2 (0.9) ^a,b	27.0 (1.7) ^a,c	23.7 (1.9) ^b,c	< .001
Genetic risk scores
PRS‐PD	1.97 (0.17)	1.95 (0.23)	1.91 (0.20)	.369
PRS‐AD	‐0.10 (0.62) ^a,b	0.68 (0.78) ^a	0.86 (0.95) ^b	< .001
MRI analysis	34 (61.8)	50 (57.5)	24 (53.3)	.696

Abbreviations: α‐syn, α‐synuclein; Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; MRI, magnetic resonance imaging; NC, normal cognition; PD, Parkinson's disease; PRS, polygenic risk score; p‐tau, phosphorylated tau.

Notes: Results from the analysis of variance or chi‐square test as appropriate. Data are expressed as the mean (standard deviation) or number (%).

A significant difference between NC and MCI^a, NC and dmentia^b, and MCI and dementia groups^c.